A Second Course of Antithyroid Drug Therapy for Recurrent Graves' Disease: An Experience in Endocrine Practice - oneGRAVESvoice
Global Search
Global Search

Trusted Resources: Evidence & Education

Scientific literature and patient education texts

Back to Evidence & Education / Scientific Articles

A Second Course of Antithyroid Drug Therapy for Recurrent Graves’ Disease: An Experience in Endocrine Practice

key information

source: European Journal of Endocrinology / European Federation of Endocrine Societies

year: 2015

authors: Liu X, Qiang W, Liu X, Liu L, Liu S, Gao A, Gao S, Shi B

summary/abstract:

Objective:
There are scarce reports regarding the prognosis of a second course of antithyroid drug (ATD) therapy on recurrent Graves’ disease (GD). The aim of this study was to assess the long-term remission rate after a second ATD therapy and verify significant clinical predictors of a remission.

Design:
A prospective randomized clinical trial with long-term follow-up was conducted to evaluate the effects of a second course of ATD therapy.

Methods:
A total of 128 recurrent GD patients who had finished a first regular ATD therapy were enrolled in this study, and prescribed methimazole (MMI) treatment with titration regimen. The patients were randomly assigned to two groups when the drug doses were reduced to 2.5 mg daily (qd). Group 1 was discontinued with 2.5 mg qd after about 5 months. Group 2 was continuously reduced to 2.5 mg every other day (qod) after 5 months and then discontinued with 2.5 mg qod after about a further 5 months. The patients were followed for 48 months after drug withdrawal.

Results:
Of the total number of patients, 97 cases (75.78%) achieved permanent remission at the end of follow-up, with the recurrence of 31 cases (24.22%). The remission rate of group 2 (84.62%) was significantly higher than that of group 1 (66.67%) (P=0.024). Cox regression showed that the hazard ratio for recurrence decreased under a high or high normal TSH level at drug withdrawal.

Conclusion:
A second course of ATD therapy can bring about a satisfying long-term remission on recurrent GD. The drug dose of 2.5 mg qod and a high or high normal TSH level at drug withdrawal may increase the likelihood of permanent remission.

organization: First Affiliated Hospital of Xi'an Jiaotong University, China

DOI: 10.1530/EJE-14-0704

read more full text

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Powered by

Brought to you by

Supported through an independent
educational grant by

© 2022 rareLife solutions Inc.